NVTA Stock Recent News

Invitae Corporation (NYSE:NVTA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President & CEO Ana Schrank - CFO Conference Call Participants Isabella Prugue - Leerink Partners Tom Stevens - Cowen Madison Pasterchick - Morgan Stanley Dustin Scaringe - William Blair Rachel Vatnsdal - JP Morgan Operator Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today's call.

The headline numbers for Invitae (NVTA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash.

Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability.

While penny stocks offer high potential gains, they are among the riskiest sub-$5 investments an investor can make. The low stock price penny stocks offer often reflects weak business models, high debt, and uncertain prospects.

- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO , Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization.

Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the shares of NVTA stock are up today.

The genetic testing company is reducing costs to improve margins.

Invitae has struggled to turn rising revenue into profit. Last year, the company launched a strategic plan to pave the way to positive cash flow and is making some progress.